-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target

Benzinga·09/03/2026 11:14:08
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Scribe Therapeutics (NASDAQ:SCTX) with a Buy and maintains $60 price target.